| CAPIVASERTIB | None | ||
| 160MG, 200MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. | |||
|
Yes
| |||
| TRUQAP | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 |
|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||
| *********** *******[*,*-*]********** ** * ******* ****** * ********* | *********** ***** ** (*)-*-*****-*-(*-(*-************)-*-*************)-*-(**-*******[*,*-*]*********-*-**) **********-*-*********** | *********** ***** ** (*)-*-*****-*-(*-(*-************)-*-*************)-*-(**-*******[*,*-*] *********-*-**) **********-*-*********** | ******* ****** * ********** | ******* ****** * ********** | ******* ****** * ********** | ******* ****** * ********** | *****-********* ******** *** ********** *********** (*.*., *******) ** ******* ******* ********** | *****-********* ******** *** ********** *********** (*.*., *******) ** ******* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|